| Not All Bispecifics Engage T Cells: Insights from Mechanism to Management |
|
In this Educator Module, Kevin Chen, PharmD, MS, BCOP, CPP, of UNC Health, and Leigh Ann Childress, MSN, CRNP, AOCNP, of Clearview Cancer Institute, provide a clear overview of T-cell–engager and non–T-cell–engager bispecific therapies. They outline how differences in molecular design shape toxicity profiles, monitoring needs, and supportive care strategies. Case studies illustrate practical approaches to identifying and managing adverse events, helping advanced practitioners optimize care for patients receiving these novel agents.
Take a short survey and earn your certificate of participation!
APSHO members: Login here to take the survey and download your certificate. APSHO non-members: Create an APSHO guest non-member profile first by clicking here. Once you’ve created your APSHO profile, follow the prompts to the survey and the certificate. Meet The Faculty
Co-Author
Kevin Y. Chen, PharmD, MS, BCOP, CPP
UNC Health Kevin Y. Chen is a clinical pharmacist practitioner at University of North Carolina (UNC) Medical Center specializing in the care of patients with thoracic malignancies and sarcoma. His clinical interests center around precision medicine,
dose-optimization of targeted therapies, and pharmacoeconomics. Kevin also holds an adjunct faculty position at the UNC Eshelman School of Pharmacy, where he hopes to expand our knowledge of evidence-based assessments for experiential
education.
Co-Author
Leigh Ann Childress, MSN, CRNP, AOCNP
Clearview Cancer Institute Leigh Ann Childress has practiced in the field of oncology nursing for 25 years. She currently serves as a nurse practitioner and Director of Advanced Practice at Clearview Cancer Institute and is passionate about advancing the practice
and education of APPs in the community oncology setting.
|